AMG-337   Click here for help

GtoPdb Ligand ID: 8913

Synonyms: AMG 337 | compound 24 [PMID: 19819693]
PDB Ligand
Compound class: Synthetic organic
Comment: AMG337 is an investigational inhibitor of the MET proto-oncogene receptor tyrosine kinase (a.k.a. hepatocyte growth factor receptor or c-MET). It has been designed to decrease its inhibitory effect on CYP3A4 metabolic activity (i.e. its liability of inhibiting hepatic drug metabolism) [1-2]. AMG337 is the R-enantiomer and it adopts a U-shaped binding mode in the kinase ATP binding pocket. The S-enantiomer is unable to interact in the same pocket.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 101.36
Molecular weight 463.18
XLogP 4.44
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COCCOc1cnc2c(c1)c(=O)n(cc2)C(c1nnc2n1cc(cc2F)c1cnn(c1)C)C
Isomeric SMILES COCCOc1cnc2c(c1)c(=O)n(cc2)[C@@H](c1nnc2n1cc(cc2F)c1cnn(c1)C)C
InChI InChI=1S/C23H22FN7O3/c1-14(30-5-4-20-18(23(30)32)9-17(11-25-20)34-7-6-33-3)21-27-28-22-19(24)8-15(13-31(21)22)16-10-26-29(2)12-16/h4-5,8-14H,6-7H2,1-3H3/t14-/m1/s1
InChI Key DWHXUGDWKAIASB-CQSZACIVSA-N
No information available.
Summary of Clinical Use Click here for help
AMG337 is being evaluated in Phase 2 clinical trials for efficacy as an antineoplastic therapy for MET amplified solid tumours of the stomach and esophagus- see NCT02344810 and NCT02016534 for example.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02016534 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Phase 2 Interventional Amgen
NCT02344810 C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Phase 1/Phase 2 Interventional Eastern Cooperative Oncology Group